Summary
Most ovarian cancer will relapse after standard therapy. Patients with recurrent ovarian cancer are resistant to platinum. Due to the high heterogeneity between ovarian cancer, individual precise therapy is of great importance. The study will establish ovarian cancer organoids, whose original tissues from the patients with advanced or recurrent ovarian cancer, their tumors cannot be excised completely. The organoids will be identified at the histopathological level and gene level for evaluating the consistency with the original tumor tissue. The drug's sensitivity and specificity are detected through the organoids model. Compared with the clinical efficiency of the actual drug regimen, the efficacy of the organoid drug screening model can be assessed. The aim is to construct a precise drug screening platform for advanced and recurrent ovarian cancer patients and innovate drug research and development.
Key Facts
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: 1. Patients voluntarily participated in the study and signed informed consent; 2. The tumour cannot be excised thoroughly by surgery; 3. ECOG score ≤ 2; 4. Expected survival \>6 months; 5. Blood routine test: Hb≥70g/L、WBC≥3.5×109/ L 、ANC≥1.5×109/L、PLT≥80×109/L; 6. Both serum ALT and serum AST ≤ 2 × ULN； blood creatinine ≤ 1.5 × ULN; 7. Unpregnant women (negative HCG) received contraception in the study; 8. Good compliance is judged by researchers. Exclusion Criteria: 1. Active or the uncontrol serious infections; 2. Patients with liver cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis need antiviral treatment; 3. A history of immune deficiency, including HIV positive or other acquired congenital immune deficiency diseases; 4. Chronic renal insufficiency and renal failure; 5. Myocardial infarction, severe arrhythmia and congestive heart failure (≥ grade 2 according to NYHA classification); 6. Autoimmune diseases, including systemic lupus erythematosus; 7. Patients take drugs that damage liver and kidney function for other complications, such as tuberculosis; 8. Patients cannot understand the experimental contents and refuse to sign the informed consent form; 9. Other concomitant serious diseases harm the health of patients or interfere with the study.